With 1.25 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.85 million shares. The 52-week range on CDNA shows that it touched its highest point at $34.84 and its lowest point at $7.42 during that stretch. It currently has a 1-year price target of $32.06. Beta for the stock currently stands at 2.14.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CDNA was down-trending over the past week, with a drop of -2.82%, but this was down by -12.88% over a month. Three-month performance dropped to -18.51% while six-month performance fell -34.33%. The stock gained 90.79% in the past year, while it has lost -5.18% so far this year. A look at the trailing 12-month EPS for CDNA yields 1.02 with Next year EPS estimates of -0.02. For the next quarter, that number is -0.21. This implies an EPS growth rate of -148.39% for this year and 96.44% for next year.
Float and Shares Shorts:
At present, 54.77 million CDNA shares are outstanding with a float of 51.92 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CDNA since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.79979 being high and -$1.0283 being low. For CDNA, this leads to a yearly average estimate of -$0.895. Based on analyst estimates, the high estimate for the next quarter is $0.17 and the low estimate is $0.12. The average estimate for the next quarter is thus $0.13.
Summary of Insider Activity:
Insiders traded CDNA stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.
